Dr. Magdalene Moran is the Chief Executive Officer of Topo Therapeutics. She received her PhD in Neurobiology from Harvard University where she was advised by ion channel expert Dr. David Clapham. For more than 20 years, Dr. Moran has led drug discovery efforts on transmembrane protein targets implicated in pain, pulmonary, CNS and renal diseases, advancing 4 programs from inception into the clinic with large pharma partners. Most recently, Dr. Moran was the President and Chief Scientific Officer of Caraway Therapeutics, where she built out operations, drove scientific strategy, and led drug discovery efforts for multiple challenging ion channel targets from the company’s inception through its acquisition by Merck in November 2023.